Remove 2026 Remove Healthcare Remove Physicians
article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026.

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

Strategy #1: innovate and create Amazon founder Jeff Bezos has said that overnight success takes about 10 years — and that ramp-up period may be what’s playing out for the ecommerce giant in healthcare. billion, following an earlier failed healthcare venture with Berkshire Hathaway and JPMorgan Chase.

Retail 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Health consumers: A long way off

World of DTC Marketing

We keep hearing the term “consumers of health” but the American healthcare system is too profitable to allow people to be consumers of healthcare. What if … people got a fair ROI for healthcare spending the way we expect a reasonable return from other investments? By 2026, national health expenditures will reach $5.7

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

article thumbnail

Making Sense of the Latest Changes to the Market Access Landscape

PM360

Most immediately, it will add confusion in the healthcare space,” explains Daniel Sontupe, Associate Partner, Managing Director, The Bloc Value Builders. This will create confusion in the marketplace and may possibly lead to delivery of misinformation to healthcare providers (HCPs) regarding a brand’s drug coverage,” Bambalas says.

article thumbnail

Pharma’s pain from the Inflation Reduction Act will be felt well beyond the first 10 brands facing price cuts

Clarivate

Starting in 2026, the first ten self-administered Part D drugs in the law’s cross hairs will receive price cuts of 38%-79%. With the passage of the Inflation Reduction Act (IRA), the United States government gained the ability to directly negotiate drug prices with manufacturers.